within Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IX12_Fluciclovine18f;

model Fluciclovine18f
  extends Pharmacolibrary.Drugs.ATC.V.V09IX12;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>V09IX12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fluciclovine (18F), also known as 18F-fluciclovine or Axumin, is a radiolabeled synthetic amino acid and PET imaging agent used primarily for positron emission tomography (PET) imaging in the detection of recurrent prostate cancer. It is an approved radiotracer for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult human males with suspected recurrent prostate cancer undergoing PET imaging studies with fluciclovine (18F).</p><h4>References</h4><ol><li><p>Tade, FI, et al., &amp; Schuster, DM (2016). Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 57(9) 1357–1363. DOI:<a href=\"https://doi.org/10.2967/jnumed.115.171389\">10.2967/jnumed.115.171389</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27056619/\">https://pubmed.ncbi.nlm.nih.gov/27056619</a></p></li><li><p>Asano, Y, et al., &amp; Hayakawa, K (2011). Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[18F]FACBC. <i>Annals of nuclear medicine</i> 25(6) 414–418. DOI:<a href=\"https://doi.org/10.1007/s12149-011-0477-z\">10.1007/s12149-011-0477-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21409348/\">https://pubmed.ncbi.nlm.nih.gov/21409348</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fluciclovine18f;
